[1]刘　成.不同剂量瑞舒伐他汀钙对脑梗死合并高脂血症患者血脂水平、血管内皮功能及神经功能的影响[J].新乡医学院学报,2021,38(5):453-457.[doi:10.7683/xxyxyxb.2021.05.012]
　LIU Cheng.Effect of different doses of rosuvastatin calcium on blood lipid level,vascular endothelial function and neurological function of patients with cerebral infarction and hyperlipidemia[J].Journal of Xinxiang Medical University,2021,38(5):453-457.[doi:10.7683/xxyxyxb.2021.05.012]
点击复制

不同剂量瑞舒伐他汀钙对脑梗死合并高脂血症患者血脂水平、血管内皮功能及神经功能的影响
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
38
期数:
2021年5
页码:
453-457
栏目:
临床研究
出版日期:
2021-05-05

文章信息/Info

Title:
Effect of different doses of rosuvastatin calcium on blood lipid level,vascular endothelial function and neurological function of patients with cerebral infarction and hyperlipidemia
作者:
刘　成
（黄河三门峡医院神经内科，河南　三门峡　472000）
Author(s):
LIU Cheng
(Department of Neurology,Huanghe Sanmenxia Hospital,Sanmenxia 472000,Henan Province,China)
关键词:
瑞舒伐他汀钙; 脑梗死; 高脂血症; 血脂; 血管内皮功能; 神经功能缺损
Keywords:
rosuvastatin calciumcerebral infarctionhyperlipidemiablood lipidvascular endothelial functionneurologic impairment
分类号:
R743.3
DOI:
10.7683/xxyxyxb.2021.05.012
文献标志码:
A
摘要:
目的　探讨不同剂量瑞舒伐他汀钙对脑梗死合并高脂血症患者血脂水平、血管内皮功能及神经功能的影响。方法　选择2018年1月至2018年12月黄河三门峡医院收治的220例脑梗死合并高脂血症患者为研究对象，所有患者给予瑞舒伐他汀钙治疗，根据瑞舒伐他汀钙使用剂量将患者分为A组（n=117）和B组（n=103）。A组患者给予瑞舒伐他汀钙10 mg，口服，每日1次；B组患者给予瑞舒伐他汀钙20 mg，口服，每日1次；疗程均为1个月。对2组患者治疗前和治疗后血清总胆固醇（TC）、三酰甘油（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）、血管内皮细胞生长因子（VEGF）、内皮素-1（ET-1）、一氧化氮（NO）水平进行比较；治疗前和治疗后，采用美国国立卫生研究院卒中量表（NIHSS）评估患者神经功能缺损情况，采用Barthel指数（BI）评估患者生活活动能力；治疗1个月后评估患者临床疗效；观察治疗期间患者不良反应发生情况。结果　治疗前2组患者血清TC、TG、HDL-C、LDL-C水平比较差异均无统计学意义（P＞0.05）；与治疗前比较，治疗后2组患者血清TC、TG、LDL-C水平显著降低，血清HDL-C水平显著升高（P＜0.05）；治疗后，B组患者血清TC、TG、LDL-C水平显著低于A组，血清HDL-C水平显著高于A组（P＜0.05）。治疗前2组患者血清VEGF、ET-1、NO水平比较差异均无统计学意义（P＞0.05）；与治疗前比较，治疗后2组患者血清VEGF、NO水平显著升高，血清ET-1水平显著降低（P＜0.05）；治疗后，B组患者血清VEGF、NO水平显著高于A组，血清ET-1水平低于A组（P＜0.05）。治疗前2组患者NIHSS评分、BI评分比较差异均无统计学意义（P＞0.05）；与治疗前比较，治疗后2组患者NIHSS评分显著降低，BI评分显著升高（P＜0.05）；治疗后，B组患者NIHSS评分显著低于A组，BI评分显著高于A组（P＜0.05）。A组和B组患者治疗总有效率分别为86.32%（101/117）、95.14%（98/103），B组患者总有效率显著高于A组（χ2=3.967，P＜0.05）。A组和B组患者不良反应发生率分别为6.83%（8/117）、6.79%（7/103），2组患者不良反应发生率比较差异无统计学意义（χ2=0.001，P＞0.05）。结论　与低剂量瑞舒伐他汀钙（10 mg·d-1）比较，高剂量（20 mg·d-1）瑞舒伐他汀钙可更好地调节脑梗死合并高脂血症患者的血脂水平，改善血管内皮功能和神经功能。
Abstract:
Objective　To investigate the effect of different doses of rosuvastatin calcium on blood lipid levels,vascular endothelial function and neurological function of patients with cerebral infarction and hyperlipidemia.Methods　　A total of 220 patients with cerebral infarction and hyperlipidemia admitted to Huanghe Sanmenxia Hospital from January 2018 to December 2018 were selected as the research subjects.All patients were treated with rosuvastatin calcium,and the patients were divided into group A (n=117) and group B (n=103) according to the dosage of rosuvastatin calcium.The patients in the group A were treated with 10 mg rosuvastatin calcium,while the patients in the group B were treated with rosuvastatin calcium 20 mg by oral,once a day for one month.The levels of serum total cholesterol (TC),triglyceride (TG),high density lipoprotein cholesterol (HDL-C),low density lipoprotein cholesterol (LDL-C),vascular endothelial growth factor (VEGF),endothelin-1 (ET-1) and nitric oxide (NO) were compared between the two groups before and after treatment.Before and after treatment,the neurologic impairment of patients was evaluated by the National Institutes of Health Stroke Scale (NIHSS),and the activity of life was evaluated by Barthel index (BI).The adverse reactions of patients were observed during the treatment,and the clinical efficacy was evaluated after one month of treatment.Results　There was no significant difference in serum TC,TG,HDL-C and LDL-C levels between the two groups before treatment (P＞0.05).Compared with before treatment,the levels of serum TC,TG and LDL-C after treatment were significantly decreased,while the level of serum HDL-C after treatment was significantly increased in the two groups (P＜0.05).After treatment,the levels of serum TC,TG and LDL-C in the group B were significantly lower than those in the group A,and the level of serum HDL-C in the group B was significantly higher than that in the group A (P＜0.05).There was no significant difference in serum VEGF,ET-1 and NO levels between the two groups before treatment (P＞0.05).Compared with before treatment,the levels of serum VEGF and NO after treatment were significantly increased,and the level of serum ET-1 after treatment was significantly decreased in the two groups (P＜0.05).After treatment,the serum VEGF and NO levels in the group B were significantly higher than those in the group A,and the serum ET-1 level was lower than that in the group A (P＜0.05).There was no significant difference in NIHSS score and BI score between the two groups before treatment (P＞0.05).Compared with the before treatment,the NIHSS score after treatment was significantly decreased,and the BI score after treatment was significantly increased in the two groups (P＜0.05).After treatment,the NIHSS score in the group B was significantly lower than that in the group A,and the BI score in the group B was significantly higher than that in the group A (P＜0.05).The total effective rate in the group A and group B was 86.32% (101/117) and 95.14% (98/103),respectively.The total effective rate in the group B was significantly higher than that in the group A (χ2=3.967,P＜0.05).The incidence of adverse reactions in the group A and group B was 6.83% (8/117) and 6.79% (7/103),respectively.There was no significant difference in the incidence of adverse reactions between the two groups (χ2=0.001,P＞0.05).Conclusion　Compared with low-dose rosuvastatin calcium (10 mg·d-1),high-dose rosuvastatin calcium (20 mg·d-1) can better regulate the blood lipid level,improve vascular endothelial function and neurological function in patients with cerebral infarction and hyperlipidemia.

参考文献/References:

［1］　BATURINA O,MIRONOVA O.Clinical case of hyperlipidemia type Ⅳ in a man with diabetes,myocardial infarction and stroke［J］.Atherosclerosis,2017,26(3):e227-e228.
［2］　吉凤，徐小林.三种他汀类药物治疗老年动脉粥样硬化性急性脑梗死合并高血脂效果对比观察［J］.山东医药，2014，54（28）：50-52.
［3］　黄立宏，冯小芳，黄流清，等.脑梗死二级预防中他汀类药物的应用情况及中断他汀类药物治疗对预后和复发的影响［J］.中国老年学杂志，2017，37（3）：631-633.
［4］　项广宇.氯吡格雷联合阿托伐他汀钙治疗短暂性脑缺血发作疗效观察［J］.新乡医学院学报，2019，36（1）：86-89.
［5］　谢坚，张虹桥，章成国，等.瑞舒伐他汀与阿托伐他汀对急性脑梗死患者血脂、血清超敏C反应蛋白及颈动脉粥样硬化斑块作用的比较［J］.临床神经病学杂志，2015，28（1）：37-41.
［6］　张俊华，于明，苏建华，等.瑞舒伐他汀对脑梗死合并颈动脉粥样硬化患者神经功能缺损及血清炎性因子水平的影响［J］.临床神经病学杂志，2014，27（3）：196-198.
［7］　中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2014［J］.中华神经科杂志，2018，51（9）：666-670.
［8］　诸骏仁，高润霖，赵水平，等.中国成人血脂异常防治指南：2016年修订版［J］.中国循环杂志，2016，16（10）：15-35.
［9］　中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南：2016年修订版［J］.中国循环杂志，2016，31（10）：937-950.
［10］　RIZWANULLAH M,AMIN S,AHMAD J.Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers［J］.J Drug Target,2017,25(1):58-74.
［11］　SIMONSON S G,MARTIN P D,MITCHELL P D,et al.Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics［J］.J Clin Pharmacol,2015,45(8):927-934.
［12］　杨娟，李禄金，何迎春，等.瑞舒伐他汀钙治疗中国高脂血症人群的药效动力学探索［J］.中国临床药理学与治疗学，2010，15（8）：894-900.
［13］　吕建峰，罗万权，张兴梅，等.不同强度他汀对中青年冠心病患者支架植入术后血脂水平的影响及安全性［J］.重庆医科大学学报，2015，40（4）：511-515.
［14］　张兰芳，齐晓勇，贾新未，等.不同剂量瑞舒伐他汀对急性心肌梗死经皮冠状动脉介入治疗患者心肌再灌注及心功能的影响［J］.中国临床药理学杂志，2015，31（13）：1223-1226.
［15］　MACPHERSON M,HAMRN B,BRAAMSKAMP M J,et al.Population pharmacokinetics of rosuvastatin in pediatric patients with heterozygous familial hypercholesterolemia［J］.Eur J Clin Pharmacol,2016,72(1):19-27.
［16］　陆阳，雷明锐，徐淼，等.瑞舒伐他汀剂量加倍和联合普罗布考治疗冠心病合并高胆固醇血症患者的疗效比较［J］.第二军医大学学报，2015，36（1）：83-86.
［17］　ZHANG Z L,ZHANG L Z,MA X R,et al.GW25-e1169 effect of different dose of rosuvastatin on the levels of serum adiponectin,vWF and endothelial function in patients with acute coronary syndrome［J］.J Am Coll Cardiol,2014,64(16):C127.
［18］　陈坤山，徐国平，王金鹏，等.银杏达莫注射液对急性脑梗死患者脑血流及血管内皮功能的影响［J］.中成药，2014，36（12）：2479-2482.
［19］　卢利萍，桑德春，白帆，等.脑梗死患者康复治疗前后血管内皮生长因子水平的比较［J］.中国康复理论与实践，2016，22（12）：1434-1437.
［20］　AYDIN M U,AYGUL N,ALTUNKESER B B,et al.Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters,oxidized-LDL and inflammatory markers in ST elevation myocardial infarction［J］.Atherosclerosis,2015,239(2):439-443.
［21］　ABEYSINGHE H C S,LAITA B,DUSTING G J,et al.Brain remodelling following endothelin-1 induced stroke in conscious rats［J］.PLoS One,2014,9(5):e970-e977.
［22］　李真，李伟，陈琦，等.不同剂量瑞舒伐他汀治疗急性脑梗死的临床观察［J］.中国药房，2017，28（14）：1948-1951.
［23］　王太昊，岑运光.瑞舒伐他汀片治疗急性心肌梗死的临床研究［J］.中国临床药理学杂志，2018，34（7）：756-759.

相似文献/References:

[1]王泰安.复方丹参联用纳络酮治疗急性脑梗死31例[J].新乡医学院学报,2001,18(04):278.
[2]陈 娟,吕文国.黄芪注射液联合复方丹参注射液治疗急性脑梗死30例[J].新乡医学院学报,2002,19(02):083.
[3]李素芳,王艳.降纤酶联用低分子肝素治疗脑梗死疗效观察[J].新乡医学院学报,2002,19(06):502.
[4]刘世峰,刘江峰.降纤酶与东菱克栓酶治疗急性脑梗死的临床对照观察[J].新乡医学院学报,2002,19(04):291.
[5]张思莲.脑梗死患者患侧股骨颈骨折术后护理[J].新乡医学院学报,2002,19(05):441.
[6]汪裕荣.灯盏花注射液治疗急性脑梗死128例[J].新乡医学院学报,2002,19(01):050.
[7]丁泽昌,吕荣亚.降纤酶治疗脑梗死40例临床疗效观察[J].新乡医学院学报,2003,20(06):438.
[8]崔光琴,王凯。.脑梗死70例急性期血压变化[J].新乡医学院学报,2003,20(06):447.
[9]张晨光,沈琪琳,马振武,等.急性脑梗死患者血液流变学及血细胞参数的变化[J].新乡医学院学报,2003,20(03):177.
[10]周俐红,陈 娟.老年脑梗死合并感染30例分析[J].新乡医学院学报,2003,20(03):210.

更新日期/Last Update: 2021-05-05